Pfs25H-EPA/Alhydrogel传播阻断疫苗在健康马里成人中的安全性与免疫原性:随机双盲对照剂量递增研究
该随机双盲对照剂量递增试验在马里成人中评估Pfs25H-EPA/Alhydrogel传播阻断疫苗的安全性与免疫原性,疫苗组报告了更多征集性不良事件,第四剂后抗体滴度达峰值但随后快速下降,标准膜喂养试验显示血清传播阻断活性显著高于对照,但直接皮肤喂养未证实传播阻断。
要点
- Pfs25H疫苗组报告了更多征集性不良事件(137 vs 86,p=0.022)和治疗相关不良事件(191 vs 126,p=0.034)。
- 第四剂后抗Pfs25H抗体几何均值峰值422.3 ELISA单位(95%CI 290-615),半衰期42天。
- 第四剂后标准膜喂养试验血清传播阻断活性Pfs25H组高于对照(p<0.001),但直接皮肤喂养未证实。
核心结论
- Pfs25H-EPA/Alhydrogel耐受性良好,标准膜喂养试验显示显著血清活性,但每周直接皮肤喂养未证实传播阻断活性。
- 该活性需要四剂接种,第四剂后滴度快速下降,应评估替代抗原或联合方案以提高活性。
研究设计与样本
- 在马里Bancoumana开展的双盲、随机、对照、剂量递增试验,分试点安全性评估和主阶段两阶段进行。
- 试点安全性队列20人按1:1区组随机分配接受Pfs25H-EPA/Alhydrogel 16 μg或Euvax B对照疫苗两剂。
- 主队列100人按1:1区组随机分配接受Pfs25H-EPA/Alhydrogel 47 μg或对照疫苗(第一、二、三剂为Euvax B,第四剂为Menactra)。
- 纳入18-45岁健康村民,要求实验室检查正常(包括HIV、乙肝、丙肝检测)且未接受过疟疾疫苗或近期免疫抑制药物、疫苗或血制品。
- 主要结局为所有受种者的安全性和耐受性,次要结局为按方案人群接种后14天的免疫原性。
主要发现
- 2013年5月15日至6月16日筛查230人,试点安全性队列入组20人(Pfs25H 16 μg组10人,对照疫苗组10人),主队列入组100人(Pfs25H 47 μg组50人,对照疫苗组50人)。
- 与对照疫苗组相比,Pfs25H疫苗组有更多征集性不良事件(137起 vs 86起,p=0.022)和治疗相关不良事件(191起 vs 126起,p=0.034),其他不良事件数量在两组间无差异(792起 vs 683起)。
- Pfs25H抗体滴度随每剂接种升高,第四剂后几何均值峰值为422.3 ELISA单位(95%CI 290-615),此后相对快速下降,抗Pfs25H半衰期42天,抗EPA半衰期59天。
- 第600天与峰值滴度比值中位数抗Pfs25H为0.19 vs 抗EPA为0.29(p=0.009)。
- 第四剂后血清传播阻断活性Pfs25H组高于对照疫苗组(p<0.001),第三剂后两组无显著差异(p=0.09)。
临床怎么用
- 原文结论未据此给出临床推荐。
- 作者认为应评估替代抗原或联合方案以提高活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pfs25H-EPA is a protein-protein conjugate transmission-blocking vaccine against Plasmodium falciparum that is safe and induces functional antibodies in malaria-naive individuals. In this field trial, we assessed Pfs25H-EPA/Alhydrogel for safety and functional immunogenicity in Malian adults. METHODS: This double-blind, randomised, comparator-controlled, dose-escalation trial in Bancoumana, Mali, was done in two staggered phases, an initial pilot safety assessment and a subsequent main phase. Healthy village residents aged 18-45 years were eligible if they had normal laboratory results (including HIV, hepatitis B, hepatitis C tests) and had not received a previous malaria vaccine or recent immunosuppressive drugs, vaccines, or blood products. Participants in the pilot safety cohort and the main cohort were assigned (1:1) by block randomisation to a study vaccine group. Participants in the pilot safety cohort received two doses of Pfs25H-EPA/Alhydrogel 16 μg or Euvax B (comparator vaccine), and participants in the main cohort received Pfs25H-EPA/Alhydrogel 47 μg or comparator vaccine (Euvax B for the first, second, and third vaccinations and Menactra for the fourth vaccination). Participants and investigators were masked to group assignment, and randomisation codes in sealed envelopes held by a site pharmacist. Vials with study drug for injection were covered by opaque tape and labelled with a study identification number. Group assignments were unmasked at final study visit. The primary outcomes were safety and tolerability for all vaccinees. The secondary outcome measure was immunogenicity 14 days after vaccination in the per-protocol population, as confirmed by the presence of antibodies against Pfs25H measured by ELISA IgG and antibody functionality assessed by standard membrane feeding assays and by direct skin feeding assays. This trial is registered with ClinicalTrials.gov, number NCT01867463. FINDINGS: Between May 15, and Jun 16, 2013, 230 individuals were screened for eligibility. 20 individuals were enrolled in the pilot safety cohort; ten participants were assigned to receive Pfs25H-EPA/Alhydrogel 16 μg, and ten participants were assigned to receive comparator vaccine. 100 individuals were enrolled in the main cohort; 50 participants were assigned to receive Pfs25H-EPA/Alhydrogel 47 μg, and 50 participants were assigned to receive comparator vaccine. Compared with comparator vaccinees, Pfs25H vaccinees had more solicited adverse events (137 events vs 86 events; p=0·022) and treatment-related adverse events (191 events vs 126 events, p=0·034), but the number of other adverse events did not differ between study vaccine groups (792 vs 683). Pfs25H antibody titres increased with each dose, with a peak geometric mean of 422·3 ELISA units (95% CI 290-615) after the fourth dose, but decreased relatively rapidly thereafter, with a half-life of 42 days for anti-Pfs25H and 59 days for anti-EPA (median ratio of titres at day 600 to peak, 0·19 for anti-Pfs25H vs 0·29 for anti-EPA; p=0·009). Serum transmission-reducing activity was greater for Pfs25H than for comparator vaccine after the fourth vaccine dose (p<0·001) but not after the third dose (p=0·09). Repeated direct skin feeds were well tolerated, but the number of participants who infected at least one mosquito did not differ between Pfs25H and comparator vaccinees after the fourth dose (p=1, conditional exact). INTERPRETATION: Pfs25H-EPA/Alhydrogel was well tolerated and induced significant serum activity by standard membrane feeding assays but transmission blocking activity was not confirmed by weekly direct skin feed. This activity required four doses, and titres decreased rapidly after the fourth dose. Alternative antigens or combinations should be assessed to improve activity. FUNDING: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
引用
- Sagara I, Healy SA, Assadou MH, et al. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. Lancet Infect Dis. 2018. PMID: 30061051. doi:10.1016/S1473-3099(18)30344-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。